1. 厚生労働省,第5回NDBオープンデータ(平成30年度).https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177182.html.
2. 国立がん研究センターがん情報サービス「がん統計」(全国がん登録). https://ganjoho.jp/reg_stat/statistics/data/dl/index.html#a14, 2018.
3. Al-Lamki RS, Lu W, Finlay S, Twohig JP, Wang EC, Tolkovsky AM, Bradley JR. DR3 signaling protects against cisplatin nephrotoxicity mediated by tumor necrosis factor. Am J Pathol. 180, 1454-1464. 2012.
4. Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol. 287, 543-549. 2004.
5. Araya CE, Fennell RS, Neiberger RE, Dharnidharka VR. Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol. 1, 1161-1166. 2006.
6. Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 53,394-401. 1998.
7. Baumgartner-Nielsen J, Olesen AB. Treatment of Skin Calcifications with Intra-lesional Injection of Sodium Thiosulphate: A Case Series. Acta Derm Venereol. 96, 257-258. 2016.
8. Bennett WM, Elzinga LW, Porter GA. Tubulointerstitial disease and toxic nephropathy. In The Kidney. WB Saunders company, Philadelphia, 993-1039. 1991.
9. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 121, 4210-4221. 2011.
10. Borch RF, Katz JC, Lieder PH, Pleasants ME. Effect of diethyldithiocarbamate rescue on tumor response to cis-platinum in a rat model. Proc Natl Acad Sci U S A. 77, 5441- 5444. 1980.
11. Bourbouze R, Baumann FC, Bonvalet JP, Farman N. Distribution of N-acetyl-beta-D- glucosaminidase isoenzymes along the rabbit nephron. Kidney Int. 25, 636–642, 1984.
12. Boylan JW. Symposium on proteinuria and renal protein catabolism. Introduction. Kidney Int. 16, 247-429. 1979.
13. Chary KK, Higby DJ, Henderson ES, Swinerton KD. Phase 1 study of high-dose cis- dichlorodiammineplatinum (II) with forced diuresis. Cancer Treat ReP. 61, 367-370. 1977.
14. Chau BN, Xin C, Hartner J, Ren S, Castano AP, Linn G, Li J, Tran PT, Kaimal V, Huang X, Chang AN, Li S, Kalra A, Grafals M, Portilla D, MacKenna DA, Orkin SH, Duffield JS. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med. 15, 121ra18. 2012.
15. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 16, 3365- 3370. 2005.
16. Christensen S, Petersen JS, Steiness E, Andreasen F. Dose dependence of proximal and distal tubular effects of furosemide in conscious rats. J Pharmacol Exp Ther. 241, 987-993. 1987.
17. Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sørensen HT. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med. 22, 399-406. 2011.
18. Chun R, Knapp DW, Widmer WR, Glickman NW, DeNicola DB, Bonney PL. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993). J Am Vet Med Assoc. 209, 1588-1591. 1996.
19. Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 43, 1104-1108. 2004.
20. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 63, 809-825. 2003.
21. Daugaard G, Abildgaard U, Larsen S, Holstein-Rathlou NH, Amtorp O, Olesen HP, Leyssac PP. Functional and histopathological changes in dog kidneys after administration of cisplatin. Ren Physiol. 10, 54-64. 1987.
22. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S, Star RA. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 60, 2118-2128. 2001.
23. Dennis DL, Fletcher WS. Toxicity of sodium thiosulfate (NSC-45624), a nitrogen mustard antagonist, in the dog. Cancer Chemother Rep. 50, 255-257. 1966.
24. Du J, Cao X, Zou L, Chen Y, Guo J, Chen Z, Hu S, Zheng Z. MicroRNA-21 and risk of severe acute kidney injury and poor outcomes after adult cardiac surgery. PLoS One. 8, e63390. 2013.
25. Fan PC, Chen CC, Chen YC, Chang YS, Chu PH. MicroRNAs in acute kidney injury. Hum Genomics. 10, 29. 2016.
26. García E, López R, Álvarez-Del-Vayo C, Bernabeu-Wittel J. Iatrogenic Calcinosis Cutis Successfully Treated with Topical Sodium Thiosulfate. Pediatr Dermatol. 34, 356-358. 2017.
27. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 39, 1362-1371. 1977.
28. Goossens J, Courbebaisse M, Caudron E, Bahans C, Vacquerie V, Melchior J, Salle PV, Moesch C, Daudon M, Frocht V, Richette P, Ea HK, Guigonis V. Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases. Semin Arthritis Rheum. 47, 451-455. 2017.
29. Hatae M, Tezuka H, Ushiki N, Ezono Y, Igyuin H, Terahara M, Hokanishi H. Intraperitoneal and intrapleural two channel chemotherapy by cisplatinum (DDP) and sodium thiosulfate for the treatment of ovarian cancer. Gan To Kagaku Ryoho. 11, 433-439. 1984.
30. Hatiboglu I, Mihich E, Moore GE, Nichol CA. Use of sodium thiosulfate as a neutralizing agent during regional administration of nitrogen mustard: an experimental study. Ann Surg. 156, 994-1001. 1962.
31. Helfand SC, Hamilton TA, Hungerford LL, Jeglum KA, Goldschmidt MA. Comparison of three treatments for transitional cell carcinoma of the bladder in the dog. J Am Anim Hosp Assoc. 30, 270-275. 1994.
32. Howell SB, Taetle R. Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep. 64, 611-616. 1980.
33. Ichii O, Otsuka S, Ohta H, Yabuki A, Horino T, Kon Y. MicroRNA expression profiling of cat and dog kidneys. Res Vet Sci. 96, 299-303. 2014.
34. Ichii O, Ohta H, Horino T, Nakamura T, Hosotani M, Mizoguchi T, Morishita K, Nakamura K, Hoshino Y, Takagi S, Sasaki N, Takiguchi M, Sato R, Oyamada K, Kon Y. Urinary exosome-derived microRNAs reflecting the changes of renal function and histopathology in dogs. Sci Rep. 7:40340. 2017.
35. Ishizawa M, Taniguchi S, Baba T. Protection by sodium thiosulfate and thiourea against lethal toxicity of cis-diamminedichloroplatinum (II) in bacteria and mice. Jpn J Pharmacol. 31, 883-889. 1981.
36. Ismail OZ, Zhang X, Wei J, Haig A, Denker BM, Suri RS, Sener A, Gunaratnam L. Kidney injury molecule-1 protects against Galpha12 activation and tissue damage in renal ischemia-reperfusion injury. Am J Pathol. 185, 1207-1215. 2015.
37. Ito S. In vitro study of the juxtaglomerular apparatus and its implications in the chronic kidney disease. Hypertension. 65, 970-975. 2015.
38. JIVROSG-0808 (RADPLAT Japan, maxillary carcinoma-II) Cisplatinum (CDDP) transarterial chemoradiptherapy for patients with maxillary carcinoma, pahse II study. https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.gi?Recptno=R000010 505.
39. Joh K, Furusato M, Aizawa S, Shibazaki T, lshimoto F, Miyahara T, Usui N, Tahara H, Muramatsu Y, Maekawa K, Watanabe N, Kobayashi A. Clinical and pathological study on drugs induced nephropathies in autopsy cases. Jikeikai Med. J, 33, 365-377. 1986.
40. Jost J, Bahans C, Courbebaisse M, Tran TA, Linglart A, Benistan K, Lienhardt A, Mutar H, Pfender E, Ratsimbazafy V, Guigonis V. Topical Sodium Thiosulfate: A Treatment for Calcifications in Hyperphosphatemic Familial Tumoral Calcinosis? J Clin Endocrinol Metab. 101, 2810-2815. 2016.
41. Knapp DW, Henry CJ, Widmer WR, Tan KM, Moore GE, Ramos-Vara JA, Lucroy MD, Greenberg CB, Greene SN, Abbo AH, Hanson PD, Alva R, Bonney PL. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med. 27, 126-133. 2013.
42. Knauf H, Mutschler E. Pharmacodynamic and kinetic considerations on diuretics as a basis for differential therapy. Klin Wochenschr. 69, 239-250. 1991.
43. Koba F, Tsuji H, Abe R, Asoh T, Miyazaki S, Shirasaka C, Takeuchi Y, Arinaga S, Wada T, Uchida I, Akiyoshi T, Baba T. Intra-arterial infusion through 2 routes in liver (primary and metastatic cancer. Jpn J Cancer Chemother. 10, 1684-1690. 1983.
44. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA, Ayala AG, Shuster JJ, Abelson HT, Simone JV, Vietti TJ. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 314, 1600-1606. 1986.
45. Marrer E, Dieterle F. Impact of biomarker development on drug safety assessment. Toxicol Appl Pharmacol. 243, 167-179. 2010.
46. McDuffie JE, Sablad M, Ma J, Snook S. Urinary parameters predictive of cisplatin- induced acute renal injury in dogs. Cytokine. 52, 156-162. 2010.
47. Miller MH, Toops TC. Acute cyanide poisoning; recovery with sodium thiosulfate therapy. J Indiana State Med Assoc. 44, 1164. 1951.
48. Moore AS, Cardona A, Shapiro W, Madewell BR. Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra. A retrospective study of 15 dogs. J Vet Intern Med. 4, 148-152. 1990.
49. Naruse I, Keino H, Kawarada Y. Antibody against single-stranded DNA detects both programmed cell death and drug-induced apoptosis. Histochemistry. 101, 73-78. 1994.
50. Nojiri O, Nakamura M, Tanaka Y, Banno T. Two-route chemotherapy by CDDP and STS in liver metastasis of gastrointestinal adenocarcinoma. Gan To Kagaku Ryoho. 15, 47-51. 1988.
51. Ogilvie GK, Krawiec DR, Gelberg HB, Twardock AR, Reschke RW, Richardson BC. Evaluation of a short-term saline diuresis protocol for the administration of cisplatin. Am J Vet Res. 49, 1076-1078. 1988.
52. Onohara S, Sonoda T, Oyama T, Kobayashi H, Uchiyama N, Yamaguchi K, Shinohara S. Two Route Infusion Therapy of Cisplatin using Balloon Catheter for Primary Liver Cancer- With Special Reference to its Provisional Effects and Side Effects and side effects. Nihon Igaku Hoshasen Gakkai Zasshi. 44, 700-706. 1984.
53. Ortiz A, Lorz C, Catalán MP, Danoff TM, Yamasaki Y, Egido J, Neilson EG. Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. Kidney Int. 57, 969-981. 2000.
54. Ostrow S, Egorin MJ, Hahn D, Markus S, Aisner J, Chang P, LeRoy A, Bachur NR, Wiernik PH. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep. 65, 73-78. 1981.
55. Ouchi A, Asano M, Aono K, Watanabe T, Kato T. Comparison of short and continuous hydration regimen in chemotherapy containing intermediate- to high-dose Cisplatin. J Oncol. 2014:767652. 2014.
56. Page R, Matus RE, Leifer CE, Loar A. Cisplatin, a new antineoplastic drug in veterinary medicine. J Am Vet Med Assoc. 186, 288-290. 1985.
57. Pfeifle CE, Howell SB, Felthouse RD, Woliver TB, Andrews PA, Markman M, Murphy MP. High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol. 3, 237-244. 1985.
58. Pritchard JD, Mavligit GM, Benjamin RS, Patt YZ, Calvo DB, Hall SW, Bodey GP, Wallace S. Regression of regionally confined melanoma with intra-arterial cis- dichlorodiammineplatinum(II). Cancer Treat Rep. 63, 555-558. 1979.
59. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 110, 835-842. 2002.
60. Ren GL, Zhu J, Li J, Meng XM. Noncoding RNAs in acute kidney injury. J Cell Physiol. 234, 2266-2276. 2019.
61. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 222, 385-386. 1969.
62. Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 25, 753-758. 1984.
63. Saikumar J, Hoffmann D, Kim TM, Gonzalez VR, Zhang Q, Goering PL, Brown RP, Bijol V, Park PJ, Waikar SS, Vaidya VS. Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci. 129, 256-267. 2012.
64. Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 52, 13-18. 2003.
65. Sasaki A, Sasaki Y, Iwama R, Shimamura S, Yabe K, Takasuna K, Ichijo T, Furuhama K, Satoh H. Comparison of renal biomarkers with glomerular filtration rate in susceptibility to the detection of gentamicin-induced acute kidney injury in dogs. J Comp Pathol. 151, 264-270. 2014
66. Sato R, Soeta S, Miyazaki M, Syuto B, Sato J, Miyake Y, Yasuda J, Okada K, Naito Y. Clinical availability of urinary N-acetyl-beta-D-glucosaminidase index in dogs with urinary diseases. J Vet Med Sci. 64, 361-365. 2002.
67. Sekine H, Fukui I, Yamada T, Igarashi K, Yokokawa M, Yosida T. Double channel chemotherapy with intra-arterial infusion of DDP and concurrent intra-venous infusion of sodium thiosulfate (STS) in bladder cancer. Hinyokika Kiyo. 32. 43-48. 1986.
68. Selby NM, Crowley L, Fluck RJ, McIntyre CW, Monaghan J, Lawson N, Kolhe NV. Use of electronic results reporting to diagnose and monitor AKI in hospitalized patients. Clin J Am Soc Nephrol. 7, 533-540. 2012.
69. Shapiro MD, Bagley J, Latz J, Godwin JG, Ge X, Tullius SG, Iacomini J. MicroRNA expression data reveals a signature of kidney damage following ischemia reperfusion injury. PLoS One. 6. e23011. 2011.
70. Singh AP, Junemann A, Muthuraman A, Jaggi AS, Singh N, Grover K, Dhawan R. Animal models of acute renal failure. Pharmacol Rep. 64, 31-44. 2012.
71. Slatopolsky E, Elkan IO, Weerts C, Bricker NS. Studies on the characteristics of the control system governing sodium excretion in uremic man. J Clin Invest. 47, 521-530. 1968.
72. Stark JJ, Howel SB. Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin Pharmacol Ther. 23, 461-466. 1978.
73. Troìa R, Gruarin M, Grisetti C, Serafini F, Magna L, Monari E, Giunti M, Dondi F. Fractional excretion of electrolytes in volume-responsive and intrinsic acute kidney injury in dogs: Diagnostic and prognostic implications. J Vet Intern Med. 32, 1372-1382. 2018.
74. Uozumi J, Sagiyama K, Taniguchi S, Iwamoto Y, Aoki K, Baba T. "Two route infusion chemotherapy" using cis-Diamminedichloroplatinum (II) and its antidote, sodium thiosulfate, for metastatic liver tumors in rats. Jpn J Surg. 12, 456-462. 1982
75. Valli VE, Norris A, Jacobs RM, Laing E, Withrow S, Macy D, Tomlinson J, McCaw D, Ogilvie GK, Pidgeon G, Henderson RA. Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival. J Comp Pathol. 113, 113-130. 1995.
76. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 4, 307-320. 2005.
77. Wang JF, Zha YF, Li HW, Wang F, Bian Q, Lai XL, Yu G. Screening plasma miRNAs as biomarkers for renal ischemia-reperfusion injury in rats. Med Sci Monit. 20, 283-289. 2014 a.
78. Wang W, Li J, Zhu W, Gao C, Jiang R, Li W, Hu Q, Zhang B. MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis. BMC Cancer 14, 819. 2014 b.
79. Watany MM, Hagag RY, Okda HI. Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study. Clin Chem Lab Med. 56, 739-747. 2018.
80. Yagoda A, Watson RC, Gonzalez-Vitale JC, Grabstald H, Whitmore WF. Cis- dichlorodiammineplatinum (II) in advanced bladder cancer. Cancer Treat Rep. 60, 917- 923. 1976.
81. Yoshida K, Takahashi T, Nakame Y, Saitoh H, Horiuchi S, Kaneoya F, Negishi T. Acute change in urinary NAG activity following CDDP administration. Hinyokika Kiyo. 32, 369-373. 1986.
82. Yoshida T, Niho S, Toda M, Goto K, Yoh K, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study. Jpn J Clin Oncol. 44, 346-354. 2014.
83. Yonezawa A. Molecular mechanism underlying delivery of platinum agents to the cancer and kidney. Drug Delivery System. 27, 381-388. 2012.
84. Zheng JS, Jing-Nie, Zhu TT, Ruan HR, Xue-Wei, Rui-Wu. Screening of Early Diagnostic Markers of Gentamicin-induced Acute Kidney Injury in Canines. J Vet Res. 63, 405-411. 2019.